

Xue-Zhong Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3234006/publications.pdf>

Version: 2024-02-01

113
papers

3,314
citations

126858

33
h-index

168321

53
g-index

113
all docs

113
docs citations

113
times ranked

5553
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA-31 regulates T-cell metabolism via HIF1 α and promotes chronic GVHD pathogenesis in mice. <i>Blood Advances</i> , 2022, 6, 3036-3052.	2.5	7
2	Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. <i>Leukemia</i> , 2022, 36, 1907-1915.	3.3	7
3	Expression of GM-CSF Is Regulated by Fli-1 Transcription Factor, a Potential Drug Target. <i>Journal of Immunology</i> , 2021, 206, 59-66.	0.4	14
4	A single strain of <i>Bacteroides fragilis</i> protects gut integrity and reduces GVHD. <i>JCI Insight</i> , 2021, 6, .	2.3	43
5	Ageing-dependent mitochondrial dysfunction mediated by ceramide signaling inhibits antitumor T cell response. <i>Cell Reports</i> , 2021, 35, 109076.	2.9	35
6	Interleukin-23 receptor signaling by interleukin-39 potentiates T cell pathogenicity in acute graft-versus-host disease. <i>American Journal of Transplantation</i> , 2021, 21, 3538-3549.	2.6	9
7	Nuclear PFKF promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	23
8	XBP-1s Promotes B Cell Pathogenicity in Chronic GVHD by Restraining the Activity of Regulated IRE-1 α -Dependent Decay. <i>Frontiers in Immunology</i> , 2021, 12, 705484.	2.2	1
9	STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function. <i>Cellular and Molecular Immunology</i> , 2021, 18, 632-643.	4.8	5
10	S1P/S1PR1 Signaling Required for Optimal T-Cell Pathogenicity to Induce Gvhd By Regulating Drp1/mTOR Axis. <i>Blood</i> , 2021, 138, 643-643.	0.6	0
11	Ridd Is Required for the Prevention of Chronic Gvhd By Targeting IRE-1 α /Xbp-1s Signaling. <i>Blood</i> , 2021, 138, 1681-1681.	0.6	0
12	Targeting Pim2 for Improving T-Cell Effector Function and Promoting Cancer Immunotherapy. <i>Blood</i> , 2021, 138, 1720-1720.	0.6	0
13	Donor T-Cell Repertoire Profiling in Recipient Lymphoid and Parenchyma Organs Reveals GVHD Pathogenesis at Clonal Levels After Bone Marrow Transplantation in Mice. <i>Frontiers in Immunology</i> , 2021, 12, 778996.	2.2	3
14	Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease. <i>Clinical Cancer Research</i> , 2020, 26, 3481-3490.	3.2	7
15	Clarifying the translational potential of B-109. <i>Nature Chemical Biology</i> , 2020, 16, 1152-1152.	3.9	2
16	Cereblon harnesses Myc-dependent bioenergetics and activity of CD8 $^+$ T lymphocytes. <i>Blood</i> , 2020, 136, 857-870.	0.6	18
17	Lysosomal Acid Lipase Is Required for Donor T Cells to Induce Graft-versus-Host Disease. <i>Cell Reports</i> , 2020, 33, 108316.	2.9	5
18	RNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity. <i>Science Advances</i> , 2020, 6, eaaz3865.	4.7	32

#	ARTICLE	IF	CITATIONS
19	Sting Negatively Regulates Allogeneic T-Cell Responses By Constraining Antigen-Presenting Cell Function. <i>Blood</i> , 2020, 136, 37-38.	0.6	0
20	Editorial: Pathogenesis and Therapy of Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2019, 10, 1797.	2.2	6
21	Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity. <i>Cell Reports</i> , 2019, 28, 1879-1893.e7.	2.9	71
22	T-Cell Costimulation and Coinhibition in Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect. , 2019, , 167-194.		2
23	Modelling CAR-T therapy in humanized mice. <i>EBioMedicine</i> , 2019, 40, 25-26.	2.7	13
24	The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease. <i>Frontiers in Immunology</i> , 2019, 10, 988.	2.2	46
25	Thioredoxin-1 improves the immunometabolic phenotype of antitumor T cells. <i>Journal of Biological Chemistry</i> , 2019, 294, 9198-9212.	1.6	28
26	Vitamin C stabilizes CD8+ iTregs and enhances their therapeutic potential in controlling murine GVHD and leukemia relapse. <i>Blood Advances</i> , 2019, 3, 4187-4201.	2.5	16
27	Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. <i>Clinical Cancer Research</i> , 2019, 25, 1036-1049.	3.2	41
28	Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice. <i>Blood</i> , 2019, 133, 266-279.	0.6	55
29	Thioredoxin-1 confines T cell alloresponse and pathogenicity in graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2019, 129, 2760-2774.	3.9	28
30	Fli-1 Regulates Multiple T-Cell Subsets during Inflammatory Responses and Experimental Graft-Versus-Host Disease. <i>Blood</i> , 2019, 134, 3201-3201.	0.6	1
31	Microrna-31 Regulates T-Cell Metabolism Via HIF1 α and Promotes Effector Function. <i>Blood</i> , 2019, 134, 623-623.	0.6	0
32	Potential Role of IL-39 in the Development of Gvhd. <i>Blood</i> , 2019, 134, 3206-3206.	0.6	0
33	Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 1582-1587.	3.3	59
34	MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice. <i>Blood</i> , 2018, 131, 1974-1986.	0.6	51
35	IL-17A α Th17 in GvHD. <i>Cellular and Molecular Immunology</i> , 2018, 15, 282-283.	4.8	3
36	CD38-NAD ⁺ Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. <i>Cell Metabolism</i> , 2018, 27, 85-100.e8.	7.2	197

#	ARTICLE	IF	CITATIONS
37	Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells. JCI Insight, 2018, 3, .	2.3	22
38	2050 Identifying the role and immunobiological mechanisms of Fli-1 mediated pathogenicity in graft Versus host disease. Journal of Clinical and Translational Science, 2018, 2, 14-15.	0.3	0
39	Stabilization of Foxp3 by Targeting JAK2 Enhances Efficacy of CD8 Induced Regulatory T Cells in the Prevention of Graft-versus-Host Disease. Journal of Immunology, 2018, 201, 2812-2823.	0.4	26
40	Inhibition of the IRE-1 β /XBP-1 pathway prevents chronic GVHD and preserves the GVL effect in mice. Blood Advances, 2018, 2, 414-427.	2.5	18
41	T-Cell Metabolism in Hematopoietic Cell Transplantation. Frontiers in Immunology, 2018, 9, 176.	2.2	29
42	Inducible T-Cell Co-Stimulator Impacts Chronic Graft-Versus-Host Disease by Regulating Both Pathogenic and Regulatory T Cells. Frontiers in Immunology, 2018, 9, 1461.	2.2	19
43	PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. Journal of Clinical Investigation, 2018, 128, 2787-2801.	3.9	28
44	Association of Donor T Cell Repertoire in Host Lymphoid and Target Organs and Gvhd Development. Blood, 2018, 132, 4525-4525.	0.6	0
45	Vitamin C Stabilizes CD8 α Tregs and Enhances Their Therapeutic Potential in Controlling GvHD and Leukemia Relapse. Blood, 2018, 132, 4532-4532.	0.6	0
46	IL-27 Receptor Signaling on T cells Augments GVHD Severity through Enhancing Th1 Responses. Journal of Immunology Research and Therapy, 2018, 3, 151-157.	1.0	2
47	Regulatory B cells promote graft-versus-host disease prevention and maintain graft-versus-leukemia activity following allogeneic bone marrow transplantation. Oncoimmunology, 2017, 6, e1284721.	2.1	28
48	T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. Blood, 2017, 130, 146-155.	0.6	54
49	Ceramide synthesis regulates T cell activity and GVHD development. JCI Insight, 2017, 2, .	2.3	49
50	Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. Oncotarget, 2017, 8, 30199-30216.	0.8	32
51	Abstract 5820: Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. , 2017, , .		0
52	Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice. Molecular Therapy - Oncolytics, 2016, 3, 16032.	2.0	25
53	CD8 ⁺ Tregs promote GVHD prevention and overcome the impaired GVL effect mediated by CD4 ⁺ Tregs in mice. Oncoimmunology, 2016, 5, e1146842.	2.1	48
54	Lower incidence of acute GVHD is associated with the rapid recovery of CD4 ⁺ CD25 ⁺ CD45RA ⁺ regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohort-based study. Oncoimmunology, 2016, 5, e1242546.	2.1	11

#	ARTICLE	IF	CITATIONS
55	Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 247-259.	2.0	35
56	T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice. <i>Journal of Immunology</i> , 2016, 196, 3168-3179.	0.4	9
57	Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation. <i>Journal of Clinical Investigation</i> , 2016, 126, 1337-1352.	3.9	107
58	Enhance T Cell Immunotherapy By Targeting PIM-2 Kinase. <i>Blood</i> , 2016, 128, 815-815.	0.6	1
59	Inhibition of Alternative Complement Pathway in Target Organs Represents a Novel and Effective Approach to Control Gvhd While Sparing GVL Effect. <i>Blood</i> , 2016, 128, 807-807.	0.6	0
60	Therapeutic Targeting of PIM Protein Kinases in a Subset of T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 2742-2742.	0.6	0
61	Prevention of Chronic Gvhd By Targeting Xbp-1 Genetically or Pharmacologically in Mice. <i>Blood</i> , 2016, 128, 4541-4541.	0.6	0
62	MiR-17-92 Is Required for the Pathogenicity of T and B Cells in Chronic Gvhd. <i>Blood</i> , 2016, 128, 4535-4535.	0.6	0
63	Regulatory T-Cell Therapy for Graft-versus-host Disease. <i>Journal of Immunology Research and Therapy</i> , 2016, 1, 1-14.	1.0	27
64	MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice. <i>Blood</i> , 2015, 126, 1314-1323.	0.6	58
65	Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1195-1204.	2.0	26
66	MicroRNA-31 negatively regulates peripherally derived regulatory T-cell generation by repressing retinoic acid-inducible protein 3. <i>Nature Communications</i> , 2015, 6, 7639.	5.8	76
67	NF- κ B-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis. <i>Nature Communications</i> , 2015, 6, 7652.	5.8	191
68	HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2015, 195, 717-725.	0.4	25
69	Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype. <i>Journal of Hematology and Oncology</i> , 2015, 8, 13.	6.9	44
70	T-bet Is Critical for the Development of Acute Graft-versus-Host Disease through Controlling T Cell Differentiation and Function. <i>Journal of Immunology</i> , 2015, 194, 388-397.	0.4	37
71	Targeting JAK2 By Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection By Promoting Induced Treg Differentiation. <i>Blood</i> , 2015, 126, 1874-1874.	0.6	5
72	Targeting Host Complement C3a/C5a Receptors to Control of Acute Graft-Versus-Host Disease in Mice. <i>Blood</i> , 2015, 126, 3076-3076.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice. <i>PLoS ONE</i> , 2015, 10, e0137641.	1.1	84
74	A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 41383-41397.	0.8	33
75	PIM2 Kinase Regulates T-Cell Alloresponses and Graft-Versus-Host Disease in Mice. <i>Blood</i> , 2015, 126, 3074-3074.	0.6	0
76	CD8 Tregs Promote Gvhd Prevention and Restore Impaired GVL Effect Mediated By CD4 Tregs in Mice. <i>Blood</i> , 2015, 126, 1873-1873.	0.6	0
77	NF- κ B is crucial in proximal T-cell signaling for calcium influx and NFAT activation. <i>European Journal of Immunology</i> , 2014, 44, 3741-3746.	1.6	8
78	Helper T-Cell Differentiation in Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2014, 62, 277-301.	1.0	22
79	Reducing CD73 Expression by IL1 β -Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors. <i>Cancer Research</i> , 2014, 74, 6048-6059.	0.4	49
80	Tolerance induction between two different strains of parental mice prevents graft-versus-host disease in haploidentical hematopoietic stem cell transplantation to F1 mice. <i>Biochemical and Biophysical Research Communications</i> , 2014, 446, 1035-1041.	1.0	2
81	Perfecting Adoptive Cellular Therapy for Graft-Versus-Host Disease: Alloreactive Induced T Regulatory Cells. <i>Blood</i> , 2014, 124, 3813-3813.	0.6	0
82	Microrna-17-92 Cluster: Novel Target for Controlling Gvhd While Preserving GVL Effect. <i>Blood</i> , 2014, 124, 845-845.	0.6	1
83	Allogeneic T Cells Utilize Glycolysis As the Predominant Metabolic Pathway to Induce Acute Graft-Versus-Host Disease. <i>Blood</i> , 2014, 124, 2419-2419.	0.6	2
84	T-Bet Is Critical for the Development of Acute Graft-Versus-Host Disease By Regulating Hematopoietic Antigen Presenting Cells. <i>Blood</i> , 2014, 124, 846-846.	0.6	0
85	Phosphatidylinositol 3-Kinase-Independent Signaling Pathways Contribute to ICOS-Mediated T Cell Costimulation in Acute Graft-Versus-Host Disease in Mice. <i>Journal of Immunology</i> , 2013, 191, 200-207.	0.4	19
86	Adoptive Transfer of Tc1 or Tc17 Cells Elicits Antitumor Immunity against Established Melanoma through Distinct Mechanisms. <i>Journal of Immunology</i> , 2013, 190, 1873-1881.	0.4	55
87	Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 692-702.	2.0	61
88	Rel is an essential transcription factor for the development of acute graft-versus-host disease in mice. <i>European Journal of Immunology</i> , 2013, 43, 2327-2337.	1.6	17
89	Pharmacologic inhibition of PKC δ and PKC ζ prevents GVHD while preserving GVL activity in mice. <i>Blood</i> , 2013, 122, 2500-2511.	0.6	37
90	Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease. <i>Blood</i> , 2013, 122, 2251-2261.	0.6	42

#	ARTICLE	IF	CITATIONS
91	STAT5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving CTL capacity. <i>Journal of Leukocyte Biology</i> , 2013, 95, 205-213.	1.5	28
92	Targeting PKC δ in alloreactivity and graft-versus-host-disease: unanswered questions and therapeutic potential. <i>Frontiers in Immunology</i> , 2012, 3, 259.	2.2	5
93	LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1182-1190.e1.	2.0	24
94	Genetic and Pharmacologic Inhibition of PKC δ and PKC ζ Prevents Acute Gvhd While Sparing GVL Activity in Mice. <i>Blood</i> , 2012, 120, 3000-3000.	0.6	0
95	T-Bet Is Critical for the Development of Acute Graft-Versus-Host Disease Through Controlling T Cell Differentiation and Function. <i>Blood</i> , 2012, 120, 452-452.	0.6	0
96	Dynamic Changes and Impact of Myeloid Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice. <i>Blood</i> , 2012, 120, 2999-2999.	0.6	0
97	High Efficacy of Alloantigen-Specific Induced Regulatory T Cells in the Prevention of Acute Graft-Versus-Host Disease in Mice. <i>Blood</i> , 2012, 120, 4112-4112.	0.6	0
98	Efficient and Selective Prevention of GVHD by Antigen-Specific Induced Tregs via Linked-Suppression in Mice. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 309-318.	2.0	49
99	Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 962-969.	2.0	41
100	Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. <i>Blood</i> , 2011, 118, 5671-5680.	0.6	134
101	Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and ROR γ t in mice. <i>Blood</i> , 2011, 118, 5011-5020.	0.6	136
102	Role of corticotrophin releasing hormone in cerebral infarction-related gastrointestinal barrier dysfunction. <i>World Journal of Emergency Medicine</i> , 2011, 2, 59-65.	0.5	6
103	T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 170-178.	2.0	100
104	Abundant c-Fas-associated death domain-like interleukin-1-converting enzyme inhibitory protein expression determines resistance of T helper 17 cells to activation-induced cell death. <i>Blood</i> , 2009, 114, 1026-1028.	0.6	36
105	PKC δ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 3774-3786.	3.9	70
106	CD28 Controls Differentiation of Regulatory T Cells from Naive CD4 T Cells. <i>Journal of Immunology</i> , 2008, 181, 2285-2291.	0.4	107
107	β 2 integrins separate graft-versus-host disease and graft-versus-leukemia effects. <i>Blood</i> , 2008, 111, 954-962.	0.6	47
108	Alloantigen Affinity and CD4 Help Determine Severity of Graft-versus-Host Disease Mediated by CD8 Donor T Cells. <i>Journal of Immunology</i> , 2006, 176, 3383-3390.	0.4	31

#	ARTICLE	IF	CITATIONS
109	Opposing Effects of ICOS on Graft-versus-Host Disease Mediated by CD4 and CD8 T Cells. <i>Journal of Immunology</i> , 2006, 176, 7394-7401.	0.4	43
110	Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin. <i>Blood</i> , 2005, 105, 1355-1361.	0.6	25
111	Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation. <i>European Journal of Immunology</i> , 2005, 35, 2598-2607.	1.6	77
112	Role of CD28 in Acute Graft-Versus-Host Disease. <i>Blood</i> , 1998, 92, 2963-2970.	0.6	62
113	RNA-Binding Protein PCBP1/hnRNP E1 is an Intracellular Checkpoint for Shaping Effector Versus Regulatory T Cells in Immunity and Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0